Growth Metrics

Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Regeneron Pharmaceuticals (REGN) over the last 15 years, with Q4 2025 value amounting to $4.1 billion.

  • Regeneron Pharmaceuticals' Long-Term Deferred Tax rose 2302.59% to $4.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.1 billion, marking a year-over-year increase of 2302.59%. This contributed to the annual value of $4.1 billion for FY2025, which is 2302.59% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Long-Term Deferred Tax is $4.1 billion, which was up 2302.59% from $3.8 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $4.1 billion for Q4 2025, and its period low was $723.2 million during Q3 2021.
  • Over the past 5 years, Regeneron Pharmaceuticals' median Long-Term Deferred Tax value was $2.2 billion (recorded in 2023), while the average stood at $2.2 billion.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Long-Term Deferred Tax plummeted by 1007.21% in 2021 and then soared by 10078.82% in 2022.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Long-Term Deferred Tax stood at $876.9 million in 2021, then skyrocketed by 96.57% to $1.7 billion in 2022, then skyrocketed by 49.41% to $2.6 billion in 2023, then increased by 28.68% to $3.3 billion in 2024, then increased by 23.03% to $4.1 billion in 2025.
  • Its Long-Term Deferred Tax stands at $4.1 billion for Q4 2025, versus $3.8 billion for Q3 2025 and $3.6 billion for Q2 2025.